600056 中国医药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.5283.9664.9399.3686.982
总资产报酬率 ROA (%)0.4901.2931.5802.8592.196
投入资产回报率 ROIC (%)0.8092.0782.5394.7343.594

边际利润分析
销售毛利率 (%)10.61010.50210.73611.29112.627
营业利润率 (%)3.8192.8932.7994.3073.191
息税前利润/营业总收入 (%)4.1983.1373.4614.5143.550
净利润/营业总收入 (%)2.8961.9082.0823.1992.363

收益指标分析
经营活动净收益/利润总额(%)98.308125.012121.41680.615121.618
价值变动净收益/利润总额(%)2.423-7.0276.288-0.9034.425
营业外收支净额/利润总额(%)0.499-2.3712.139-1.937-0.299

偿债能力分析
流动比率 (X)1.4231.4231.5231.5841.495
速动比率 (X)1.1111.1161.1741.2381.158
资产负债率 (%)61.04161.04460.55862.87763.312
带息债务/全部投入资本 (%)37.26037.48237.75735.64538.609
股东权益/带息债务 (%)142.009141.545137.049143.241129.484
股东权益/负债合计 (%)52.53452.58754.68749.14747.581
利息保障倍数 (X)11.67510.0835.76715.6439.648

营运能力分析
应收账款周转天数 (天)164.005138.467137.172125.141116.446
存货周转天数 (天)75.42270.25671.59064.36664.338